Organigram (OGI) Stock Price, News & Analysis

Company Overview

Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Key Stats

• Today's Range: C$1.44 to C$1.48
• 50-Day Range: C$1.45 to C$2.17
• 52-Week Range: C$1.44 to C$3.09
• Volume: 122,664 shs
• Average Volume: 219,833 shs
• Market Capitalization: C$203.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$3.13
• Consensus Rating: Buy

Organigram Stock Analysis - MarketRank™

Organigram scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Organigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Organigram has a consensus price target of C$3.13, representing about 115.5% upside from its current price of C$1.45.

Amount of Analyst Coverage

Organigram has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Organigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Organigram has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram does not currently pay a dividend.

Dividend Growth

Organigram does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Organigram has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Organigram this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Organigram insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$142,753.00 in company stock.

Percentage Held by Insiders

31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.99% of the stock of Organigram is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: TSE:OGI
• CIK: N/A
• Web: www.organigram.ca
• Phone: 844-644-4726
• Fax: N/A
• Employees: 987
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Organigram: C$3.13
• High Price Target: C$3.25
• Low Price Target: C$3.00
• Potential Upside/Downside: +115.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): C($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.88
• P/E Growth: 0.42
• Net Income: -C$57.23 million
• Net Margins: -9.19%
• Pretax Margin: N/A
• Return on Equity: -6.83%
• Return on Assets: -5.56%

Debt

• Debt-to-Equity Ratio: 2.20
• Current Ratio: 2.82
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: C$274.19 million
• Price / Sales: 0.74
• Cash Flow: C$0.38 per share
• Price / Cash Flow: 3.85
• Book Value: C$2.83 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 140,636,000
• Free Float: N/A
• Market Cap: C$203.92 million
• Optionable: Not Optionable
• Beta: 1.72